Table 1.
αS-SAA positivity as a function of pathology diagnosis.
| αS-SAA positivity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pathology | n | αSyn Pathology | Antemortem | Postmortem | Frontal | Amygdala | ||||
| AD | 26 | Negative | 4% | 1/26 | 20% | 3/14 | - | - | - | - |
| AD + VD | 5 | Negative | 0% | 0/5 | 0% | 0/3 | - | - | - | - |
| AD + VD + HS | 2 | Negative | 0% | 0/2 | 0% | 0/2 | - | - | - | - |
| AD + VD + AA | 1 | Negative | 0% | 0/1 | - | - | - | - | - | - |
| AD + AA | 3 | Negative | 0% | 0/3 | 0% | 0/1 | 0% | 0/1 | 0% | 0/1 |
| AD + HS | 1 | Negative | 0% | 0/1 | 0% | 0/1 | - | - | - | - |
| AD + HS + LMN Encephalitis | 1 | Negative | 0% | 0/1 | - | - | - | - | - | - |
| AD + Pick’s disease | 1 | Negative | 0% | 0/1 | - | - | - | - | - | - |
| AD + PART | 1 | Negative | 0% | 0/1 | - | - | - | - | - | - |
| AD + PART + METS | 1 | Negative | 0% | 0/1 | 0% | 0/1 | - | - | - | - |
| AD + VD + AA + ARTAG | 1 | Negative | 0% | 0/1 | 0% | 0/1 | 0% | 0/1 | 0% | 0/1 |
| CBD + VD + AA | 1 | Negative | 0% | 0/1 | - | - | 100%* | 1/1 | 0% | 0/1 |
| PSP | 2 | Negative | 0% | 0/2 | - | - | - | - | - | - |
| CBD | 1 | Negative | 0% | 0/1 | 0% | 0/1 | - | - | - | - |
| FTLD-TDP43 | 1 | Negative | 0% | 0/1 | 0% | 0/1 | - | - | - | - |
| FTLD-Tau | 1 | Negative | 0% | 0/1 | - | - | - | - | - | - |
| VD | 2 | Negative | 0% | 0/2 | - | - | 0% | 0/1 | 0% | 0/1 |
| Normal | 2 | Negative | 0% | 0/2 | 0% | 0/1 | - | - | - | - |
| AD + αSyn-Path | 26 | Neocortical/Limbic | 100% | 26/26 | 91% | 10/11 | 100% | 4/4 | 100% | 4/4 |
| AD + αSyn-Path | 7 | Amygdala-predominant | 14% | 1/7 | - | - | 50% | 1/2 | 100% | 1/1 |
| AD + VD + αSyn-Path | 6 | Neocortical/Limbic | 83% | 5/6 | 75% | 3/4 | 100% | 1/1 | 100% | 1/1 |
| AD + VD + αSyn-Path | 4 | Amygdala-predominant | 0% | 0/4 | 100% | 4/4 | 100%* | 1/1 | 100% | 1/1 |
| AD + AA + αSyn-Path | 2 | Neocortical | 100% | 2/2 | 100% | 2/2 | 100% | 1/1 | 100% | 1/1 |
| AD + AA + αSyn-Path | 3 | Amygdala-predominant | 0% | 0/3 | 50% | 1/2 | 0% | 0/2 | 50% | 1/2 |
| AD + AA + FTLD-TDP43 + αSyn-Path | 2 | Neocortical/Limbic | 100% | 2/2 | 100% | 1/1 | 100% | 1/1 | 100% | 1/1 |
| AD + AA + FTLD-TDP43 + αSyn-Path | 3 | Amygdala-predominant | 0% | 0/3 | 33% | 1/3 | 0% | 0/3 | 33% | 1/3 |
| AD + HS + αSyn-Path | 4 | Neocortical/Limbic | 100% | 4/4 | 100% | 1/1 | - | - | - | - |
| AD + Pick’s disease + αSyn-Path | 1 | Amygdala-predominant | 0% | 0/1 | - | - | - | - | - | - |
| AD + ARTAG + αSyn-Path | 1 | Neocortical | 100% | 1/1 | 100% | 1/1 | 100% | 1/1 | 100% | 1/1 |
| AD + VD + PSP + αSyn-Path | 1 | Amygdala-predominant | 100% | 1/1 | - | - | 0% | 0/1 | 100%* | 1/1 |
| AD + Infarcts + αSyn-Path | 1 | Amygdala-predominant | 100% | 1/1 | - | - | - | - | - | - |
| PSP + CBD + HS + αSyn-Path | 1 | Neocortical | 100% | 1/1 | - | - | - | - | - | - |
| FTLD-TDP43 + αSyn-Path | 1 | Amygdala-predominant | 0% | 0/1 | 0% | 0/1 | 0% | 0/1 | 0% | 0/1 |
| αSyn-Path | 3 | Neocortical | 100% | 3/3 | - | - | - | - | - | - |
AD:Alzheimer’s disease, VD: Vascular disease, HS: hippocampal sclerosis, AA: Includes amyloid angyopathy, leptomeningial congophilic angiopathy, and lepto/parenchymal congophilic angiopathy, LMN Encephalitis: Limbic Microglial Nodular Encephalitis , PART: Primary-Age Related Tauopathy, METS: Micrometastases, ARTAG: Aging-related tau astrogliopathy, CBD: corticobasal degeneration, PSP: progressive supranuclear palsy, FTLD-TDP43: Frontotemporal lobe degeneration with TDP43 pathology, and αSyn-Path: Includes neocortical, limbic, and amygdala predominant αSyn pathology.
*
2/3 wells were positive.